Viva Biotech Announces Subsidiary Restructuring and CFO Changes

Viva Biotech Holdings (HK:1873) has released an update.

Viva Biotech Holdings has announced the successful transformation of its subsidiary Viva Shanghai into a joint-stock company, with the parent company retaining approximately 72.9% interest. Alongside this corporate restructuring, Mr. WANG Zheren has stepped down as Co-Chief Financial Officer to concentrate on his role as CFO of Viva Shanghai, while Mr. XIONG Wei will take over as the sole CFO of the Group.

For further insights into HK:1873 stock, check out TipRanks’ Stock Analysis page.